Which has stronger earnings & valuation, OLMA or TARA?

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A

Is OLMA or TARA more profitable?

Protara Therapeutics' return on equity of -38.70% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -46.00% -41.22% Protara Therapeutics N/A -38.70% -36.02%

Which has preferable valuation & earnings, ORIC or TARA?

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.44 N/A Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A

Is ORIC or TARA more profitable?

Oric Pharmaceuticals' return on equity of -35.33% beat Protara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.33% -33.31% Protara Therapeutics N/A -38.70% -36.02%

Which has higher valuation & earnings, TARA or CGEM?

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A

Is TARA or CGEM more profitable?

Protara Therapeutics' return on equity of -38.70% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -38.70% -36.02% Cullinan Therapeutics N/A -51.45% -47.64%

Protara Therapeutics (TARA) Competitors

$4.00 -0.11 (-2.68%)

As of 06/23/2026 04:00 PM Eastern

Compare

TARA vs. ETON, OLMA, TBPH, ORIC, and CGEM

Should you buy Protara Therapeutics stock or one of its competitors? MarketBeat compares Protara Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Protara Therapeutics include Eton Pharmaceuticals (ETON), Olema Pharmaceuticals (OLMA), Theravance Biopharma (TBPH), Oric Pharmaceuticals (ORIC), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry.

How does Protara Therapeutics compare to Eton Pharmaceuticals?

Protara Therapeutics (NASDAQ:TARA) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Protara Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

In the previous week, Eton Pharmaceuticals had 3 more articles in the media than Protara Therapeutics. MarketBeat recorded 3 mentions for Eton Pharmaceuticals and 0 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 0.00 beat Eton Pharmaceuticals' score of -0.04 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Protara Therapeutics	Neutral
Eton Pharmaceuticals	Neutral

Eton Pharmaceuticals has higher revenue and earnings than Protara Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Eton Pharmaceuticals	$79.95M	11.47	-$4.60M	-$0.07	N/A

Protara Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 7.6% of Protara Therapeutics shares are held by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Protara Therapeutics currently has a consensus target price of $26.25, indicating a potential upside of 556.25%. Eton Pharmaceuticals has a consensus target price of $41.00, indicating a potential upside of 22.42%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Protara Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Protara Therapeutics beats Eton Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Protara Therapeutics compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Olema Pharmaceuticals presently has a consensus price target of $44.10, indicating a potential upside of 318.80%. Protara Therapeutics has a consensus price target of $26.25, indicating a potential upside of 556.25%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Olema Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Olema Pharmaceuticals has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

In the previous week, Olema Pharmaceuticals had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 1 mentions for Olema Pharmaceuticals and 0 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 0.00 beat Olema Pharmaceuticals' score of -1.57 indicating that Protara Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Olema Pharmaceuticals	Very Negative
Protara Therapeutics	Neutral

Protara Therapeutics' return on equity of -38.70% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Protara Therapeutics	N/A	-38.70%	-36.02%

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A

Summary

Protara Therapeutics beats Olema Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Protara Therapeutics compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, Theravance Biopharma had 3 more articles in the media than Protara Therapeutics. MarketBeat recorded 3 mentions for Theravance Biopharma and 0 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 0.00 beat Theravance Biopharma's score of -0.05 indicating that Protara Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Theravance Biopharma	Neutral
Protara Therapeutics	Neutral

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by company insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Theravance Biopharma has a net margin of 104.34% compared to Protara Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Protara Therapeutics	N/A	-38.70%	-36.02%

Theravance Biopharma has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.14	$105.89M	$2.20	7.71
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A

Theravance Biopharma presently has a consensus price target of $21.40, indicating a potential upside of 26.10%. Protara Therapeutics has a consensus price target of $26.25, indicating a potential upside of 556.25%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Theravance Biopharma has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

Summary

Theravance Biopharma beats Protara Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Protara Therapeutics compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

In the previous week, Oric Pharmaceuticals had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 1 mentions for Oric Pharmaceuticals and 0 mentions for Protara Therapeutics. Oric Pharmaceuticals' average media sentiment score of 0.00 equaled Protara Therapeutics'average media sentiment score.

Company	Overall Sentiment
Oric Pharmaceuticals	Neutral
Protara Therapeutics	Neutral

Oric Pharmaceuticals' return on equity of -35.33% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Protara Therapeutics	N/A	-38.70%	-36.02%

Oric Pharmaceuticals has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

Oric Pharmaceuticals presently has a consensus target price of $18.92, suggesting a potential upside of 112.31%. Protara Therapeutics has a consensus target price of $26.25, suggesting a potential upside of 556.25%. Given Protara Therapeutics' higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Comparatively, 7.6% of Protara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A

Summary

Oric Pharmaceuticals and Protara Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Protara Therapeutics compare to Cullinan Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 1 mentions for Cullinan Therapeutics and 0 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 0.00 equaled Cullinan Therapeutics'average media sentiment score.

Company	Overall Sentiment
Protara Therapeutics	Neutral
Cullinan Therapeutics	Neutral

38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 7.6% of Protara Therapeutics shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Protara Therapeutics' return on equity of -38.70% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

Protara Therapeutics currently has a consensus target price of $26.25, indicating a potential upside of 556.25%. Cullinan Therapeutics has a consensus target price of $32.00, indicating a potential upside of 80.28%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Protara Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Protara Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market.

Summary

Protara Therapeutics beats Cullinan Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Protara Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TARA vs. The Competition

Export

Metric	Protara Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$231M	$2.97B	$6.45B	$12.39B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-2.99	18.43	24.92	23.98
Price / Sales	N/A	327.41	528.23	109.07
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	1.05	4.11	10.79	6.50
Net Income	-$57.44M	$64.45M	$3.56B	$336.88M
7 Day Performance	-1.72%	1.41%	1.00%	-0.14%
1 Month Performance	-18.70%	1.04%	0.42%	0.77%
1 Year Performance	30.72%	23.88%	29.70%	28.49%

Protara Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
TARA Protara Therapeutics	2.3922 of 5 stars	$4.00 -2.7%	$26.25 +556.3%	+38.9%	$231M	N/A	N/A	30
ETON Eton Pharmaceuticals	4.0544 of 5 stars	$32.15 +1.8%	$41.00 +27.5%	+147.9%	$865.33M	$79.95M	N/A	20
OLMA Olema Pharmaceuticals	1.9049 of 5 stars	$9.88 +0.1%	$44.10 +346.4%	+151.3%	$862.12M	N/A	N/A	70
TBPH Theravance Biopharma	2.5174 of 5 stars	$16.32 -1.9%	$21.83 +33.8%	+60.5%	$857.84M	$107.46M	7.42	110
ORIC Oric Pharmaceuticals	1.879 of 5 stars	$8.40 +1.6%	$18.92 +125.2%	-10.9%	$856.09M	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TARA) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protara Therapeutics (TARA) Competitors

TARA vs. ETON, OLMA, TBPH, ORIC, and CGEM

How does Protara Therapeutics compare to Eton Pharmaceuticals?

Summary

How does Protara Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Protara Therapeutics compare to Theravance Biopharma?

Summary

How does Protara Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Protara Therapeutics compare to Cullinan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA vs. The Competition

Protara Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protara Therapeutics (TARA) Competitors

TARA vs. ETON, OLMA, TBPH, ORIC, and CGEM

How does Protara Therapeutics compare to Eton Pharmaceuticals?

Is TARA or ETON more profitable?

Does the media refer more to TARA or ETON?

Which has higher earnings and valuation, TARA or ETON?

Which has more risk and volatility, TARA or ETON?

Do institutionals & insiders have more ownership in TARA or ETON?

Do analysts rate TARA or ETON?

Summary

How does Protara Therapeutics compare to Olema Pharmaceuticals?

Do analysts recommend OLMA or TARA?

Do institutionals & insiders have more ownership in OLMA or TARA?

Which has more risk & volatility, OLMA or TARA?

Does the media prefer OLMA or TARA?

Is OLMA or TARA more profitable?

Which has stronger earnings & valuation, OLMA or TARA?

Summary

How does Protara Therapeutics compare to Theravance Biopharma?

Does the media favor TBPH or TARA?

Do insiders and institutionals have more ownership in TBPH or TARA?

Is TBPH or TARA more profitable?

Which has higher earnings and valuation, TBPH or TARA?

Do analysts recommend TBPH or TARA?

Which has more volatility and risk, TBPH or TARA?

Summary

How does Protara Therapeutics compare to Oric Pharmaceuticals?

Does the media favor ORIC or TARA?

Is ORIC or TARA more profitable?

Which has more risk & volatility, ORIC or TARA?

Do analysts recommend ORIC or TARA?

Do institutionals & insiders hold more shares of ORIC or TARA?

Which has preferable valuation & earnings, ORIC or TARA?

Summary

How does Protara Therapeutics compare to Cullinan Therapeutics?

Does the media refer more to TARA or CGEM?

Do insiders and institutionals believe in TARA or CGEM?

Is TARA or CGEM more profitable?

Which has higher valuation & earnings, TARA or CGEM?

Do analysts rate TARA or CGEM?

Which has more risk & volatility, TARA or CGEM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA vs. The Competition

Protara Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools